ARTICLE | Company News
Eli Lilly, TPG-Axon Capital Management L.P., Quintiles deal
July 28, 2008 7:00 AM UTC
TPG-Axon and Quintiles’ NovaQuest unit will provide Lilly about $300 million for Phase III trials of the gamma secretase inhibitor LY450139 and an unnamed antibody against beta amyloid to treat Alzh...